The clinical use of GM-CSF as an adjuvant has been evaluated for the treatment of cancer such as prostate, skin, breast, and lung cancer in an attempt to boost the antitumor immune response by increasing the efficiency of antigen presentation by dendritic cells and consequently improving T-cell activation [12,13,14]. This evidence concerns the gene CSF2 and lung cancer.